Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of Ipilimumab (Immunotherapy) and Imatinib Mesylate (c-Kit Inhibitor) in Patients With Advanced Malignancies

NCT01738139 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT01738139
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01738139 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of Ipilimumab (Immunotherapy) and Imatinib Mesylate (c-Kit Inhibitor) in Patients With Advanced Malignancies
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1
Overall status
Completed
Start date
February 19, 2013
Completion date
December 13, 2023
Enrollment
68 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant solid neoplasm, c-kit tyrosine kinase protein overexpression, clinical stage iv cutaneous melanoma ajcc v8, metastatic gastrointestinal stromal tumor, metastatic malignant solid neoplasm, metastatic melanoma, pathologic stage iv cutaneous melanoma ajcc v8, unresectable melanoma, unresectable solid neoplasm